Cargando…
Combining Everolimus and Ku0063794 Promotes Apoptosis of Hepatocellular Carcinoma Cells via Reduced Autophagy Resulting from Diminished Expression of miR-4790-3p
It is challenging to overcome the low response rate of everolimus in the treatment of patients with hepatocellular carcinoma (HCC). To overcome this challenge, we combined everolimus with Ku0063794, the inhibitor of mTORC1 and mTORC2, to achieve higher anticancer effects. However, the precise mechan...
Autores principales: | Choi, Ho Joong, Park, Jung Hyun, Kim, Ok-Hee, Kim, Kee-Hwan, Hong, Ha Eun, Seo, Haeyeon, Kim, Say-June |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998287/ https://www.ncbi.nlm.nih.gov/pubmed/33799789 http://dx.doi.org/10.3390/ijms22062859 |
Ejemplares similares
-
Everolimus Plus Ku0063794 Regimen Promotes Anticancer Effects against Hepatocellular Carcinoma Cells through the Paradoxical Inhibition of Autophagy
por: Lee, Sang Chul, et al.
Publicado: (2018) -
Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells
por: Jeon, Ye-Won, et al.
Publicado: (2022) -
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
por: García-Martínez, Juan M., et al.
Publicado: (2009) -
Isolation of Secretome with Enhanced Antifibrotic Properties from miR-214-Transfected Adipose-Derived Stem Cells
por: Park, Jung Hyun, et al.
Publicado: (2019) -
Potent Dual Inhibitors of TORC1 and TORC2 Complexes (KU-0063794 and KU-0068650) Demonstrate In Vitro and Ex Vivo Anti-Keloid Scar Activity
por: Syed, Farhatullah, et al.
Publicado: (2013)